Navigation Links
Molecular Medicine Awards 1st Annual Ross Prize to NYU Researcher
Date:2/12/2013

MANHASSET, N.Y., Feb. 12, 2013 /PRNewswire-USNewswire/ -- The Feinstein Institute for Medical Research today announced that New York University (NYU) immunology researcher Dan R. Littman , MD, PhD, will be the recipient of the first annual Ross Prize in Molecular Medicine, issued via the Feinstein Institute's peer-reviewed, open-access journal, Molecular Medicine.

(Photo: http://photos.prnewswire.com/prnh/20130212/DC58967)

Dr. Littman is the Helen L. and Martin S. Kimmel Professor of Molecular Immunology in the Skirball Institute of Biomolecular Medicine at NYU School of Medicine.  He is a Howard Hughes Medical Institute investigator, and a member of both the National Academy of Sciences and the Institute of Medicine.

The Ross award, which includes a $50,000 prize, will be formally presented to Dr. Littman on June 24 at the New York Academy of Science in Manhattan, followed by an academic lecture by Dr. Littman and several other preeminent researchers.

The Ross Prize is awarded annually by Molecular Medicine to mid-career scientists who have made a demonstrable impact in the understanding of human diseases pathogenesis and/or treatment, and who hold significant promise for making even greater contributions to the general field of molecular medicine.

"A renowned immunologist, Dr. Littman has made seminal contributions in a number of scientific fields that advance our understanding of the immune system, HIV infections and autoimmune disease," said Feinstein Institute President Kevin J. Tracey, MD, who also serves as editor-in-chief of Molecular Medicine. "Dr. Littman and his colleagues discovered that HIV enters the body through what he terms a 'Trojan horse,' a specific type of immune cell, called an immature dendritic cell, which it then hijacks to attack other key cells of the immune system.  Dr. Littman and his team have more recently discovered a means to control inappropriate autoimmune responses to bacteria that live naturally in the human digestive system."

Dr. Littman was selected by an awards committee comprised of:

  • Christopher J. Czura , PhD, vice president, scientific affairs, and executive editor, Molecular Medicine, Feinstein Institute for Medical Research;
  • Betty Diamond , MD, head, Center for Autoimmune Diseases and Musculoskeletal Disorders, Feinstein Institute;
  • Peter K. Gregersen , MD, head, Laboratory of Genomics and Human Genetics, Feinstein Institute;
  • Göran K. Hansson, MD PhD, professor of experimental cardiovascular research, Karolinska Institute, Sweden;
  • Klas Kärre, MD PhD, professor of molecular immunology, Karolinska Institute; and
  • Kevin J. Tracey , MD, President, Feinstein Institute .

The Ross Prize was made possible by the generosity of Feinstein Institute board members Robin and Jack Ross of Upper Brookville, NY.

About Molecular Medicine

Molecular Medicine is an open access, international, peer-reviewed biomedical journal published by The Feinstein Institute for Medical Research. Molecular Medicine strives to understand normal body functioning and disease pathogenesis at the molecular level, which may allow researchers and physician-scientists to use that knowledge in the design of specific molecular tools for disease diagnosis, treatment, prognosis, and prevention. To learn more, go to: www.molmed.org

About The Feinstein Institute for Medical Research

Headquartered in Manhasset, NY, The Feinstein Institute for Medical Research is home to international scientific leaders in many areas including Parkinson's disease, Alzheimer's disease, psychiatric disorders, rheumatoid arthritis, lupus, sepsis, human genetics, pulmonary hypertension, leukemia, neuroimmunology, and medicinal chemistry. The Feinstein Institute, part of the North Shore-LIJ Health System, ranks in the top 5th percentile of all National Institutes of Health grants awarded to research centers. For more information visit www.FeinsteinInstitute.org


'/>"/>
SOURCE The Feinstein Institute for Medical Research
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. A nano car with molecular 4-wheel drive
2. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
3. Chemists become molecular sculptors, synthesizing tiny, molecular traps
4. Why Medicare Carrier Proposes Major Changes in the Handling of Code Stacked Molecular Test Claims is Topic of December 20 Audio Conference
5. Amsterdam Molecular Therapeutics Announces Negative Equity Position
6. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
7. The art of molecular carpet-weaving
8. Amsterdam Molecular Therapeutics Announces € 2.5 Million Equity Raise
9. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
10. Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China
11. Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid Molecular Diagnostics Technology in Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample ... the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
Breaking Biology Technology:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/24/2016)... -- Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the ... latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Display- Ampronix News ...
Breaking Biology News(10 mins):